8,784 results match your criteria Annals Of Pharmacotherapy[Journal]


Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature.

Ann Pharmacother 2020 Jun 2:1060028020930189. Epub 2020 Jun 2.

Intermountain Healthcare, Taylorsville, UT, USA.

To compile and synthesize the available literature describing medical cannabis use across various disease states. PubMed, EBSCO, and Google Scholar searches were conducted using MeSH and/or keywords. Studies were included if they described the use of cannabis-based products and medications in the treatment of a predefined list of disease states in humans and were published in English. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020930189DOI Listing

Effects on Postoperative Gastrointestinal Motility After Neuromuscular Blockade Reversal With Sugammadex Versus Neostigmine/Glycopyrrolate in Colorectal Surgery Patients.

Ann Pharmacother 2020 May 29:1060028020929061. Epub 2020 May 29.

The University of Tennessee Medical Center, Knoxville, TN, USA.

Neuromuscular blockers (NMBs) used during surgery have historically been reversed with acetylcholinesterase inhibitors and anticholinergic agents, which can slow gastrointestinal motility. Sugammadex (SUG) provides NMB reversal with minimal effects on gastrointestinal motility. The purpose of this study was to determine if SUG for reversal of NMB is associated with decreased time to first bowel movement (BM) following laparoscopic colorectal surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020929061DOI Listing

Anti-Factor Xa Activity of Fixed-Dose Fondaparinux in Low-Body-Weight Patients With Acute Coronary Syndrome.

Ann Pharmacother 2020 May 28:1060028020930186. Epub 2020 May 28.

Chiang Mai University, Chiang Mai, Thailand.

Fixed-dose 2.5 mg of fondaparinux subcutaneous injection once daily has been recommended in treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) irrespective of body weight (BW). However, data on anti-factor Xa (anti-FXa) activity of fondaparinux are scarce in low-BW patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020930186DOI Listing

Emerging Pharmacotherapy and Health Care Needs of Patients in the Age of Artificial Intelligence and Digitalization.

Ann Pharmacother 2020 May 28:1060028020919383. Epub 2020 May 28.

University of Maryland School of Pharmacy, Baltimore, MD, USA.

Advances in the application of artificial intelligence, digitization, technology, iCloud computing, and wearable devices in health care predict an exciting future for health care professionals and our patients. Projections suggest an older, generally healthier, better-informed but financially less secure patient population of wider cultural and ethnic diversity that live throughout the United States. A pragmatic yet structured approach is recommended to prepare health care professionals and patients for emerging pharmacotherapy needs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020919383DOI Listing

Direct Oral Anticoagulants in Obesity: An Updated Literature Review.

Ann Pharmacother 2020 May 22:1060028020923584. Epub 2020 May 22.

Ascension Seton Medical Center Austin, Austin, TX, USA.

To review literature on the use of direct-acting oral anticoagulants (DOACs) in patients with high body weight (BW) and/or high body mass index (BMI) and to make recommendations regarding use in this patient population. A search using PubMed was conducted (inception to April 13, 2020) using the term AND the terms OR . A separate search was also conducted with individual DOACs (dabigatran, apixaban, rivaroxaban, edoxaban) and the aforementioned terms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020923584DOI Listing

The Use of Gentamicin for Treatment of Urogenital and Extragenital Gonorrhea: A Systematic Review of Efficacy Data.

Ann Pharmacother 2020 May 21:1060028020927057. Epub 2020 May 21.

University of Otago, Dunedin, New Zealand.

To evaluate clinical efficacy data for gentamicin in the treatment of gonorrhea. A keyword search of PubMed (1966 to April 2020), EMBASE (1947 to April 2020), and International Pharmaceutical Abstracts (1970 to April 2020) was conducted. The electronic search was supplemented with manual screening of references from identified articles and a search of ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020927057DOI Listing

The Role of Suppressing Inflammation in the Treatment of Atherosclerotic Cardiovascular Disease.

Ann Pharmacother 2020 May 19:1060028020922994. Epub 2020 May 19.

University of Connecticut School of Pharmacy, Storrs, CT, USA.

To review the 3 anti-inflammatory drugs, canakinumab, colchicine, and methotrexate, that have been investigated in major clinical trials for treating patients with atherosclerotic cardiovascular disease (ASCVD). An Ovid MEDLINE literature search (1946 to February 2, 2020) was performed using search strategy [()]. Additional references were identified from the citations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020922994DOI Listing

Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate.

Ann Pharmacother 2020 May 16:1060028020920855. Epub 2020 May 16.

University of Iowa Hospital and Clinics, Iowa City, IA, USA.

Four-factor prothrombin complex concentrate (4FPCC) is used for emergent warfarin reversal, but dosing remains controversial. Following approval, further studies have evaluated a variety of fixed-dose regimens. The studies utilized lower doses as compared with package insert dosing and provided data in regard to efficacy, safety, and cost savings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020920855DOI Listing

Clearance Confusion: An Exploratory Analysis of Inpatient Dosing Discordances Between Renal Estimating Equations.

Ann Pharmacother 2020 May 15:1060028020922492. Epub 2020 May 15.

Beaumont Hospital, Dearborn, MI, USA.

Numerous equations exist for estimating renal clearance for drug dosing, and discordance rates may be as high as 40% in certain populations. However, the populations and types of equations used in these studies may not be generalizable to broader pharmacy practice. To determine the dosing discordance rate between Cockcroft-Gault (C-G), Chronic Kidney Disease Epidemiology (CKD-EPI), and Modification of Diet in Renal Disease (MDRD) equations in a community hospital population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020922492DOI Listing

Anticoagulation Management for Impella Percutaneous Ventricular Assist Devices: An Analysis of a Single-Center Experience.

Ann Pharmacother 2020 May 15:1060028020922542. Epub 2020 May 15.

Saint Luke's Hospital of Kansas City, Kansas City, MO, USA.

Impella devices offer temporary mechanical circulatory support for cardiogenic shock. The manufacturer recommends systemic anticoagulation with a target activated clotting time of 160 to 180 s but provides no guidance on how to manage both the heparinized purge solution and the additional intravenous heparin needed to reach this therapeutic range. Previous publications demonstrated a lack of standardization in heparin management for Impella devices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020922542DOI Listing

Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.

Ann Pharmacother 2020 May 14:1060028020921166. Epub 2020 May 14.

Durham Veterans Affairs Health Care System, Durham, NC, USA.

Response-guided hepatitis C therapy was standard with interferon-based regimens but is not used for direct-acting antivirals (DAAs). Week 4 viral kinetics may predict sustained virological response (SVR) with DAAs, but it is unclear whether extending therapy in slow responders affects outcomes. The primary objective was to compare SVR rates between traditional and extended duration groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020921166DOI Listing

Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.

Ann Pharmacother 2020 May 14:1060028020921170. Epub 2020 May 14.

Samford University McWhorter School of Pharmacy, Birmingham, AL, USA.

During a recent shortage of small-volume parenteral solutions, some hospitals administered piperacillin/tazobactam via continuous infusion to utilize larger fluid volumes. Although the incidence of acute kidney injury (AKI) is well documented for patients receiving intermittent or extended-infusion piperacillin/tazobactam with concomitant vancomycin, no literature exists documenting the incidence of AKI in patients receiving continuous-infusion piperacillin/tazobactam. : The objective of this study is to examine the incidence and predictors of AKI in patients who received continuous-infusion piperacillin/tazobactam with concomitant intermittent-infusion vancomycin (VPT-CI) at a community hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020921170DOI Listing

Myth Busters: Dietary Supplements and COVID-19.

Ann Pharmacother 2020 May 12:1060028020928052. Epub 2020 May 12.

University of Connecticut, Storrs, CT, USA.

News and social media platforms have implicated dietary supplements in the treatment and prevention of coronavirus disease 2019 (COVID-19). During this pandemic when information quickly evolves in the presence of contradicting messages and misinformation, the role of the pharmacist is essential. Here, we review theoretical mechanisms and evidence related to efficacy and safety of select supplements in the setting of COVID-19, including vitamin C, vitamin D, zinc, elderberry, and silver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020928052DOI Listing

Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.

Ann Pharmacother 2020 May 9:1060028020925558. Epub 2020 May 9.

University of Florida, Gainesville, FL, USA.

The world is suffering a respiratory pandemic disease caused by a novel coronavirus (2019-nCoV), commonly known as COVID-19 (coronavirus disease 2019). The Food and Drug Administration issued an emergency authorization for chloroquine and hydroxychloroquine as experimental treatments for COVID-19 leading to a shortage of both medications. A literature review conducted in April 2020 shows a lack of high-quality data available, resulting in ambiguous guideline recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020925558DOI Listing

Opioid Prescribing After Discharge in a Previously Mechanically Ventilated, Opioid-Naïve Cohort.

Ann Pharmacother 2020 Apr 30:1060028020919122. Epub 2020 Apr 30.

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

Opioids are utilized for pain management during and after mechanical ventilation in the intensive care unit (ICU). The purpose of this study was to determine the percentage of potentially unnecessary opioid prescriptions on discharge in previously opioid-naïve patients. This retrospective cohort study included mechanically ventilated, opioid-naïve ICU patients who received opioids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020919122DOI Listing
April 2020
2.059 Impact Factor

Medication Regimen Complexity Index Prediction of Adverse Drug Reaction-Related Hospital Admissions.

Ann Pharmacother 2020 Apr 30:1060028020919188. Epub 2020 Apr 30.

University of Tasmania, Hobart, Tasmania, Australia.

The relationship between the medication regimen complexity index (MRCI) and adverse drug reaction (ADR)-related hospital admissions has not yet specifically been investigated. To evaluate the MRCI and compare with medication count for prediction of ADR-related hospital admissions in older patients. This was a retrospective analysis of a prospectively collected convenience sample of 768 unplanned medical admissions of Australians aged 65 years old and older. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020919188DOI Listing

Liposomal Amphotericin B Infusion-Related Dystonia.

Ann Pharmacother 2020 Apr 26:1060028020917632. Epub 2020 Apr 26.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020917632DOI Listing

Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients Who Have Intellectual/Developmental Disabilities in a Commercially Insured Database.

Ann Pharmacother 2020 Apr 27:1060028020916842. Epub 2020 Apr 27.

University of Michigan, Ann Arbor, MI, USA.

Patients who have intellectual/developmental disabilities (IDDs) develop atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF) at rates similar to or higher than the general population. They also face disparities accessing and using health care services. To determine if disparities exist in the use of guideline-based pharmacotherapy (GBP) for ASCVD or HF for adults with IDD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020916842DOI Listing

Impact of Automated Targeted Medication Review Electronic Alerts to Reduce Potentially Inappropriate Medication Prescribing Among Medicare Enrolled Patients With Dementia.

Ann Pharmacother 2020 Apr 22:1060028020915790. Epub 2020 Apr 22.

The Ohio State University College of Pharmacy, Columbus, OH, USA.

Background:Finding ways to reduce prescribing of potentially inappropriate medications (PIMs) among patients with dementia is necessary. To evaluate an automated targeted medication review (TMR) service to reduce PIM prescribing among patients with dementia. This was a retrospective observational analysis of patients in a Medication Therapy Management (MTM) program for year 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020915790DOI Listing

Weight Outcomes With Empagliflozin as Compared With Liraglutide in Veterans With Type 2 Diabetes Mellitus.

Ann Pharmacother 2020 Apr 10:1060028020915791. Epub 2020 Apr 10.

Department of Veterans Affairs Eastern Kansas Health Care System, Topeka, KS, USA.

Glucagon-like peptide-1 agonists and sodium glucose cotransporter 2 inhibitors are associated with weight loss and improved cardiovascular outcomes, and are increasingly used in pharmacotherapy for type 2 diabetes mellitus (T2DM). To compare weight loss outcomes of empagliflozin and liraglutide in patients with T2DM and overweight/obesity not yet prescribed insulin but requiring additional pharmacotherapy to improve glycemic control. This is an observational, multisite, cohort study of veterans with T2DM prescribed liraglutide or empagliflozin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020915791DOI Listing

Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea.

Ann Pharmacother 2020 Apr 9:1060028020915537. Epub 2020 Apr 9.

Florida State University College of Medicine, Tallahassee, FL, USA.

The purpose of this article is to review the available clinical trial data that led to the Food and Drug Administration (FDA) approval of solriamfetol as well as its role in clinical practice. A MEDLINE/PubMed search was conducted (January 2000 to February 2020) using the keyword to discover appropriate clinical trials. Articles were included that were published in the English language and related to the FDA approval of solriamfetol or provided novel information regarding this drug entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020915537DOI Listing

Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.

Ann Pharmacother 2020 Mar 23:1060028020914274. Epub 2020 Mar 23.

Southwestern Oklahoma State University College of Pharmacy, Weatherford, OK, USA.

To review the efficacy and safety of onasemnogene abeparvovec-xioi (Zolgensma) in the treatment of spinal muscular atrophy (SMA). An English-language literature search of PubMed, MEDLINE, and Ovid (1946 to December 2019) was completed using the terms , and . Manufacturer prescribing information, article bibliographies, and data from ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020914274DOI Listing

Association Between Antipsychotics and Osteoporosis Based on Real-World Data.

Ann Pharmacother 2020 Mar 18:1060028020913974. Epub 2020 Mar 18.

Kindai University, Osaka, Japan.

Osteoporosis, which is a major public health concern, has been known to reduce health-related quality of life. Some studies have suggested that antipsychotics could perhaps cause osteoporosis by increasing serum prolactin levels. However, the association between antipsychotics and the risk for developing osteoporosis has been controversial. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020913974DOI Listing

Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Ann Pharmacother 2020 Mar 16:1060028020912749. Epub 2020 Mar 16.

MCPHS University Worcester/Manchester, Worcester, MA, USA.

To review the efficacy and safety of niraparib for the treatment of recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer (OC, FTC, and PPC). A literature search via MEDLINE through PubMed from August 2013 to January 2020 was performed using the key terms , and . Completed and ongoing trials were identified through a review of the website trial registry https://www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020912749DOI Listing

Outcomes Associated With Resuming Direct Oral Anticoagulant Therapy Following Admission for a Gastrointestinal Bleed.

Ann Pharmacother 2020 Mar 6:1060028020912429. Epub 2020 Mar 6.

Wingate University, Wingate, NC, USA.

Although direct oral anticoagulants (DOACs) carry a lower bleeding risk compared with warfarin, gastrointestinal bleeds (GIB) are a known complication. There are limited data observing outcomes associated with resuming DOACs following a GIB. The purpose of this study was to evaluate practice patterns and clinical outcomes of patients admitted with an index GIB while receiving DOAC therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020912429DOI Listing

Effectiveness of Steroid Treatment for Sudden Sensorineural Hearing Loss: A Meta-analysis of Randomized Controlled Trials.

Authors:
Jinfei Li Lei Ding

Ann Pharmacother 2020 Mar 4:1060028020908067. Epub 2020 Mar 4.

Beijing University of Chinese Medicine Subsidiary Dongfang Hospital, Beijing, China.

The best way to administer steroids for sudden sensorineural hearing loss (SSHL) is still unclear. The present study was aimed at estimating the efficacy of steroids by intratympanic, systemic, and combined therapy (CT) routes. A systematic literature search was performed from 1950 to October 2019 for randomized controlled trials comparing the use of intratympanic, systemic, and combined steroid therapy for SSHL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020908067DOI Listing

Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.

Ann Pharmacother 2020 Mar 4:1060028020910439. Epub 2020 Mar 4.

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.

To review phase II and III clinical trial data to evaluate the efficacy and safety of the halobetasol propionate/tazarotene (HP/TAZ) combination lotion (Duobrii), a medication approved by the Food and Drug Administration in April 2019 for adults with plaque psoriasis. : A systematic search (January 2005 to July 2019) of MEDLINE (PubMed) and EMBASE databases was performed using the terms , and . Relevant English-language articles reporting on phase II and phase III clinical trials were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020910439DOI Listing

Looking Back at US Pharmacy's Past to Help Discern Its Future.

Ann Pharmacother 2020 Mar 1:1060028020911085. Epub 2020 Mar 1.

Touro University, Vallejo, CA, USA.

To review specific literature that aimed to predict the future of US pharmacy, beginning in the late 1980s. Articles were identified from searching MEDLINE, CINAHL, Google Scholar, and references of relevant articles. The following combinations of search terms were used: , , , and . Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020911085DOI Listing

To Block or Not: Updates in Neuromuscular Blockade in Acute Respiratory Distress Syndrome.

Ann Pharmacother 2020 Feb 28:1060028020910132. Epub 2020 Feb 28.

University of Kentucky Medical Center, Lexington, KY, USA.

To review and evaluate neuromuscular blocking agents (NMBAs) in critically ill patients with acute respiratory distress syndrome (ARDS). A literature search utilizing PubMed was performed (January 1991 to January 2020) using the following search terms: ( OR OR OR OR OR OR ) AND * OR ). Publications in English were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020910132DOI Listing
February 2020

Dose-Dependent Hyperkalemia Among Hospitalized, HIV-Infected Patients Receiving Sulfamethoxazole/Trimethoprim.

Ann Pharmacother 2020 Feb 28:1060028020909539. Epub 2020 Feb 28.

University of South Carolina College of Pharmacy, Columbia, SC, USA.

Sulfamethoxazole-trimethoprim (SXT) therapy is commonly used in HIV-infected patients and is associated with hyperkalemia and elevated serum creatinine (SCr). The purpose of this study was to examine the frequency of hyperkalemia and elevated SCr in hospitalized, HIV-infected patients receiving SXT. This was a retrospective, single-center cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020909539DOI Listing
February 2020

Improved Glycemic Control Outcomes Regardless of Mental Health Disorders in a Pharmacist-Endocrinologist Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic.

Ann Pharmacother 2020 Feb 26:1060028020908856. Epub 2020 Feb 26.

UC San Diego, La Jolla, CA, USA.

Previous studies show patients with type 2 diabetes (T2D) and a mental health (MH) disorder exhibit poorer glycemic control compared with those without. Compare mean change in glycosylated hemoglobin (A1C) after 6 months in the Diabetes Intense Medical Management (DIMM) "Tune Up" Clinic in patients with and without MH disorders. Retrospective cohort study in T2D patients, with A1C at baseline and 6 months, divided into subgroups of those with ≥1 MH diagnoses and without MH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020908856DOI Listing
February 2020

Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents.

Ann Pharmacother 2020 Feb 20:1060028020909117. Epub 2020 Feb 20.

Memorial Sloan Kettering Cancer Center, New York, NY, USA.

To discuss (1) recent and emerging data for pharmacological management of untreated and relapsed/refractory (R/R) mantle cell lymphoma (MCL) with agents approved in the United States, (2) important considerations for toxicity monitoring and management, and (3) preliminary data and ongoing studies for agents in MCL-specific clinical trials. PubMed/MEDLINE, EMBASE, Google Scholar, product labeling, National Comprehensive Cancer Network, American Cancer Society, and ClinicalTrials.gov were searched for studies published between January 1, 2017, and January 31, 2020, and key historical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020909117DOI Listing
February 2020

Standardized Volume Dosing Protocol of 23.4% Hypertonic Saline for Pediatric Critical Care: Initial Experience.

Ann Pharmacother 2020 Feb 18:1060028020907997. Epub 2020 Feb 18.

Harvard Medical School, Boston, MA, USA.

Standardized volume dosing of 23.4% hypertonic saline (HTS) exists for adults, but the concentration, dosing and administration of HTS in pediatrics is variable. With emerging pediatric experience of 23. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020907997DOI Listing
February 2020

Secukinumab-Induced Acute Autoimmune Hemolytic Anemia.

Ann Pharmacother 2020 Feb 17:1060028020907202. Epub 2020 Feb 17.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020907202DOI Listing
February 2020

The Revised Starling Equation: The Debate of Albumin Versus Crystalloids Continues.

Authors:
Brian L Erstad

Ann Pharmacother 2020 Feb 14:1060028020907084. Epub 2020 Feb 14.

University of Arizona, Tucson, AZ, USA.

The purpose of this critical narrative review is to discuss the revised Starling equation for microvascular fluid exchange and the associated implications for intravenous fluid administration. PubMed (1946 to December 2019) and EMBASE (1947 to December 2019) were used, and bibliographies of retrieved articles were searched for additional articles. Articles pertaining to the revised Starling equation and microvascular fluid exchange. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020907084DOI Listing
February 2020

Extravasation of Noncytotoxic Drugs.

Ann Pharmacother 2020 Feb 13:1060028020903406. Epub 2020 Feb 13.

Endocrine, General and Digestive Surgery Department, CHU of Limoges, Limoges, France.

Commonly used drugs may be dangerous in case of extravasation. The lack of information from health care teams can lead to delays in both diagnosis and treatments. This review aims at alerting health care professionals about drugs and risk factors for extravasation and outlines recommendations for the diagnosis and treatment of extravasation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020903406DOI Listing
February 2020
2.059 Impact Factor

Intranasal Glucagon: A New Way to Treat Hypoglycemic Emergencies.

Ann Pharmacother 2020 Feb 13:1060028020905846. Epub 2020 Feb 13.

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.

To review the safety, efficacy, and administration of intranasal (IN) glucagon for the management of hypoglycemia. A literature search of PubMed/MEDLINE (1995 to November 2019) using the terms , and was completed. English-language studies evaluating IN glucagon were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020905846DOI Listing
February 2020

Current System of Overseeing Drug Trials in Developing Countries by the FDA Is Dangerous.

Authors:
C Michael White

Ann Pharmacother 2020 Feb 10:1060028020906484. Epub 2020 Feb 10.

University of Connecticut School of Pharmacy, Storrs, CT, and Hartford Hospital, USA.

Clinical research used to substantiate Food and Drug Administration (FDA) drug approval is increasingly being conducted overseas. One of the enticements to move overseas is unequal oversight by the FDA, and these differences can result in poor quality research and human subject risk. Downstream, patients, clinicians, and payers of health care can be harmed by inaccuracies in the new drug approval process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020906484DOI Listing
February 2020

Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar).

Ann Pharmacother 2020 Feb 10:1060028020903816. Epub 2020 Feb 10.

Drake University College of Pharmacy and Health Sciences, Des Moines, IA, USA.

Basaglar, insulin glargine (BGlar; Eli Lilly, Indianapolis, IN), a follow-on biologic, was developed after the patent for Lantus, insulin glargine (LGlar; Sanofi-Aventis, Paris, France) expired. To compare the dosing and hemoglobin A (A1C)-lowering effects of BGlar compared with LGlar in a real-world setting. Adult patients, at 5 clinics, with type 1 (T1DM) or type 2 diabetes mellitus (T2DM) who were converted from LGlar to BGlar were included in this retrospective observational study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020903816DOI Listing
February 2020

The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex.

Ann Pharmacother 2020 Feb 4:1060028020904969. Epub 2020 Feb 4.

University of Tasmania, Hobart, Tasmania, Australia.

There are limited Australian data on sex differences in oral anticoagulant (OAC) prescribing in atrial fibrillation (AF) and ongoing debate regarding the optimal approach to stroke risk assessment and OAC prescribing in female patients with AF. The purpose of this study was to investigate sex differences in the prescribing of OACs in patients with AF stratified by stroke risk and in the rate of adverse outcomes. A retrospective analysis of patients admitted to the Royal Hobart Hospital (Tasmania, Australia) with nonvalvular AF between January 2011 and July 2015 was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028020904969DOI Listing
February 2020

A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.

Ann Pharmacother 2020 Feb 4:1060028019900500. Epub 2020 Feb 4.

MCPHS University, Worcester, MA, USA.

The objective of this article is to review the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, and formulary considerations of deflazacort. A search of MEDLINE and EMBASE (1946 to December 31, 2019) was conducted using the terms and (DMD). Results were limited to clinical trials, humans, and English. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019900500DOI Listing
February 2020